The MDM2 / 4 inhibitor ALRN-6924 impairs DNMT3Awt/DNMT3AR882X and induces cell cycle arrest through upregulation of p53 target genes, and MDM4 inhibition is a potential target for NK-AML patients with DNMT3AR882 [147]. Here, TP53 is linked to acute myeloid leukemia.